Meeting
2019 Gastrointestinal Cancers Symposium
A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
Authors
Takao Takahashi
Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan
Takao Takahashi , Eiji Sunami , Tetsuya Kusumoto , Mitsuyoshi Ota , Yoshiyuki Sakamoto , Naohiro Tomita , Atsuyuki Maeda , Jin Tejima , Michio Okabe , Chihiro Tanaka , Junichiro Yamauchi , Michio Itabashi , Kenjiro Kotake , Keiichi Takahashi , Hideo Baba , Narikazu Boku , Keisuke Aiba , Megumi Ishiguro , Satoshi Morita , Kenichi Sugihara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
JapicCTI-101073
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 484)
DOI
10.1200/JCO.2019.37.4_suppl.484
Abstract #
484
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.
First Author: Naohiro Tomita
Poster
2016 ASCO Annual Meeting
Planned safety analysis of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.
First Author: Takuya Miura
Poster
2019 ASCO Annual Meeting
POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.
First Author: David Lau
Poster
2018 ASCO Annual Meeting
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).
First Author: Jaafar Bennouna